Abrocitinib(CAS: 1622902-68-4)

Abrocitinib (CAS: 1622902-68-4) is regulated under various guidelines including GHS (Global Harmonized System of Classification and Labeling of Chemicals), REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) in the EU, and FDA and EPA regulations in the US. It is essential to comply with local and international regulations regarding its production, distribution, and use.

There are several alternatives to Abrocitinib (CAS: 1622902-68-4) in synthesis, including analogs like PF-06651607 and isomers such as 2R-isomer. Common alternative reagents include other JAK inhibitors like baricitinib or tofacitinib. Care should be taken to ensure the chosen alternative meets the desired pharmacological profile.

Abrocitinib (CAS: 1622902-68-4) is a market leader in the JAK inhibitor class, particularly for atopic dermatitis. Research trends indicate a focus on its efficacy and safety, with ongoing studies exploring its use in other inflammatory and autoimmune conditions. Market trends suggest continued growth and innovation.

Waste containing Abrocitinib (CAS: 1622902-68-4) should be collected in appropriate containers and disposed of via incineration or professional waste disposal services. Environmental protection should be ensured by following local regulations and guidelines. Handling should be done with caution to prevent exposure and ensure safety.